Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL721423 | 1.00 | CA1 (0.53) | CA1CA2MMP2CA9NPC1 | |
| SCHEMBL10659989 | 1.00 | CA1 (0.53) | CA1CA2MMP2CA9NPC1 | |
| Hydrochloric Acid SCHEMBL857895 | 0.98 | CA1 (0.51) | CA1CA2MMP2CA9NPC1 | |
| SCHEMBL4273509 | 0.91 | CA1 (0.49) | CA1CA2MMP2CA9NPC1 | |
| SCHEMBL28160114 | 0.86 | CA1 (0.54) | CA1CA2MMP2CA9NPC1 | |
| SCHEMBL724209 | 0.83 | ALDH1A1 (0.50) | CA1CA2MMP2CA9NPC1 | |
| SCHEMBL5819144 | 0.82 | NPC1 (0.47) | CA1CA2MMP2CA9NPC1 | |
| SCHEMBL28760175 | 0.82 | CA1 (0.45) | CA1CA2MMP2CA9NPC1 | |
| SCHEMBL28760174 | 0.82 | CA1 (0.45) | CA1CA2MMP2CA9NPC1 | |
| SCHEMBL28581036 | 0.81 | MME (0.49) | CA1CA2MMP2CA9NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 325 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106795198-B | The method for being used to prepare gemcitabine-[phenyl (benzyloxy-l-Alanine base)] phosphate | 努卡那公共有限公司 | 2019-09-06 | — | — | CN | claimed |
| CN-106795198-A | Method for preparing gemcitabine [phenyl (benzyloxy L alaninyls)] phosphate | 努卡那生物医药有限责任公司 | 2017-05-31 | — | — | CN | claimed |
| WO-2026100725-A1 | ANTI-CCR8 ANTIBODY AND ANTIBODY-DRUG CONJUGATE THEREOF | 住友ファーマ株式会社 | 2026-05-15 | — | — | WO | disclosed |
| US-12624011-B2 | Oxadiazole derivative | Sumitomo Pharma Co., Ltd. (JP) | 2026-05-12 | — | — | US | disclosed |
| EP-3971182-B1 | 2-SUBSTITUTED AMINO-NAPHTH[1,2-D]IMIDAZOL-5-ONE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | PTC THERAPEUTICS INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12590063-B2 | Phenol derivative | Sumitomo Pharma Co., Ltd. (JP) | 2026-03-31 | — | — | US | disclosed |
| US-20260042746-A1 | 2(1H)-PYRIDINIMINE DERATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2026-02-12 | — | — | US | disclosed |
| US-12534442-B2 | Benzisoxazole derivative | Sumitomo Pharma Co., Ltd. (JP) | 2026-01-27 | — | — | US | disclosed |
| US-20250382282-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2025-12-18 | — | — | US | disclosed |
| US-12427192-B2 | Water soluble adjuvant and composition containing same | Sumitomo Pharma Co., Ltd. (JP) | 2025-09-30 | — | — | US | disclosed |
| EP-4122923-B1 | OXADIAZOLE DERIVATIVE | SUMITOMO PHARMA CO LTD (JP) | 2025-09-10 | — | — | EP | disclosed |
| EP-1364945-A1 | BENZIMIDAZOLIDINONE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-11-26 | — | — | EP | disclosed |
| US-20030181496-A1 | Pyrrole derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2003-09-25 | — | — | US | disclosed |
| US-20030105323-A1 | Pyrimidine derivative | SUMITOMO PHARMACEUTICALS COMPANY LIMITED | 2003-06-05 | — | — | US | disclosed |
| EP-1310485-A1 | PYRROLE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-05-14 | — | — | EP | disclosed |
| EP-1300401-A1 | FIVE-MEMBERED-RING COMPOUND | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-04-09 | — | — | EP | disclosed |
| US-6458798-B1 | HAS AN INHIBITORY ACTIVITY OF PRODUCTION OF TH2 TYPE CYTOKINES SUCH AS IL-4, IL-5, ETC., AND IS USEFUL AS AN THERAPEUTIC AGENT FOR ALLERGIC DISEASES, AUTOIMMUNE DISEASES SUCH AS SYSTEMIC LUPUS ERYTHEMATHOSUS, ETC., AND ACQUIRED | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-10-01 | — | — | US | disclosed |
| EP-1110951-A1 | PYRIMIDINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-06-27 | — | — | EP | disclosed |
| US-4720484-A | Peptide compounds having a nitrogenous polycyclic structure | ADIR S.A.R.L. (FR) | 1988-01-19 | — | — | US | disclosed |
| EP-0094815-A2 | Oligopeptide prodrugs | SMITHKLINE BECKMAN CORPORATION (US) | 1983-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590063-B2 | Phenol derivative | HDAC3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HNF4A | CA1 2263/4885CA2 204/4885MMP2 1645/4885 |
| US-20260042746-A1 | 2(1H)-PYRIDINIMINE DERATIVE | PRNP, CLN6, CDR2 | CA1 1508/4885CA2 1558/4885MMP2 3104/4885 |
| US-20250382282-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLYL DERIVATIVE | H1-0, HTT, PRNP | CA1 1172/4885CA2 904/4885MMP2 3067/4885 |
| US-20030181496-A1 | Pyrrole derivatives | NCOA1, PKD1, NR3C2 | CA1 4634/4885CA2 1415/4885MMP2 1364/4885 |
| US-12427192-B2 | Water soluble adjuvant and composition containing same | TP53, MYD88, AQP1 | CA1 2027/4885CA2 3373/4885MMP2 2146/4885 |
| US-12624011-B2 | Oxadiazole derivative | HSD3B1, CBR3, CBR1 | CA1 43/4885CA2 26/4885MMP2 2074/4885 |
| US-20030105323-A1 | Pyrimidine derivative | IL5, IL4, IL15 | CA1 4205/4885CA2 3361/4885MMP2 3133/4885 |
| US-12534442-B2 | Benzisoxazole derivative | GABRA6, SLC6A1, GABRA1 | CA1 818/4885CA2 601/4885MMP2 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.